BR112014007616A2 - vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório - Google Patents

vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório

Info

Publication number
BR112014007616A2
BR112014007616A2 BR112014007616A BR112014007616A BR112014007616A2 BR 112014007616 A2 BR112014007616 A2 BR 112014007616A2 BR 112014007616 A BR112014007616 A BR 112014007616A BR 112014007616 A BR112014007616 A BR 112014007616A BR 112014007616 A2 BR112014007616 A2 BR 112014007616A2
Authority
BR
Brazil
Prior art keywords
respiratory syncytial
syncytial virus
vaccine
recombinant rsv
nanoparticle
Prior art date
Application number
BR112014007616A
Other languages
English (en)
Portuguese (pt)
Inventor
Smith Gale
Massare Michael
Liu Ye
Wu Yingyun
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BR112014007616A2 publication Critical patent/BR112014007616A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/115Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135Respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014007616A 2011-09-30 2012-09-27 vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório BR112014007616A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161542040P 2011-09-30 2011-09-30
US201161542721P 2011-10-03 2011-10-03
US201261611834P 2012-03-16 2012-03-16
US201261614286P 2012-03-22 2012-03-22
PCT/US2012/057546 WO2013049342A1 (en) 2011-09-30 2012-09-27 Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

Publications (1)

Publication Number Publication Date
BR112014007616A2 true BR112014007616A2 (pt) 2017-04-04

Family

ID=47996397

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007616A BR112014007616A2 (pt) 2011-09-30 2012-09-27 vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório

Country Status (14)

Country Link
US (4) US20130122032A1 (https=)
EP (1) EP2760469A4 (https=)
JP (1) JP2014530010A (https=)
KR (1) KR20140077169A (https=)
CN (2) CN105381457A (https=)
AU (1) AU2013201495B2 (https=)
BR (1) BR112014007616A2 (https=)
CA (1) CA2849471A1 (https=)
HK (1) HK1222125A1 (https=)
IL (1) IL231637A0 (https=)
MX (1) MX2014003777A (https=)
RU (1) RU2014117068A (https=)
SG (2) SG10201602434UA (https=)
WO (1) WO2013049342A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
HK1214138A1 (zh) * 2013-04-08 2016-07-22 米迪缪尼有限公司 疫苗组合物及使用方法
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
CN105087643A (zh) * 2014-04-16 2015-11-25 中国科学院上海巴斯德研究所 重组表达人呼吸道合胞病毒f1蛋白胞外区的方法及表达系统
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
CN106547635B (zh) 2015-09-18 2020-10-09 阿里巴巴集团控股有限公司 一种作业的操作重试方法和装置
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
IL262108B2 (en) * 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN106124767A (zh) * 2016-05-12 2016-11-16 广州瑞辉生物科技股份有限公司 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法
EP3518967A4 (en) 2016-10-03 2020-04-29 University of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
MX2019010948A (es) * 2017-03-15 2020-01-09 Novavax Inc Métodos y composiciones para inducir respuestas inmunitarias contra clostridium difficile.
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CN107050446B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 经修饰的季节流感-rsv联合疫苗及其制备方法
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス,インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN120227451A (zh) 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
WO2020076141A1 (ko) * 2018-10-12 2020-04-16 에스케이바이오사이언스 주식회사 재조합 rsv 생백신주 및 이의 제조 방법
EP3873517A4 (en) 2018-10-29 2022-09-28 Emory University RSV VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF
KR102725189B1 (ko) * 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
EP3932424A4 (en) * 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Rsv f/g chimeric vaccine
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230070886A1 (en) * 2020-01-27 2023-03-09 Novavax, Inc. Coronavirus vaccine formulations
AU2021250630A1 (en) * 2020-04-02 2022-10-20 Janssen Vaccines & Prevention B.V. Stabilized vaccine compositions
KR102721070B1 (ko) * 2020-11-27 2024-10-24 한국과학기술연구원 Rsvf를 발현하는 엑소좀 및 이의 용도
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023091766A2 (en) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
KR102785012B1 (ko) * 2021-12-14 2025-03-20 경희대학교 산학협력단 Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신
WO2024050015A1 (en) * 2022-09-01 2024-03-07 Novavax, Inc. Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
EP4736871A1 (en) * 2023-06-21 2026-05-06 Shenzhen Shenxin Biotechnology Co., Ltd. Respiratory syncytial virus (rsv) vaccine
WO2024259624A1 (en) * 2023-06-21 2024-12-26 Shenzhen Genius Biotech Service Co. Ltd A modified rsv f protein, a nanoparticle, a composition and a vaccine against respiratory syncytial virus infection
WO2025026448A1 (zh) * 2023-08-03 2025-02-06 广州穗和生物技术有限公司 修饰的呼吸道合胞病毒f蛋白及其用途
CN119569835A (zh) * 2023-09-07 2025-03-07 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622574A4 (en) * 2003-04-25 2006-10-18 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
WO2008114149A2 (en) * 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
US20110008838A1 (en) * 2007-07-19 2011-01-13 Gale Smith Chimeric varicella zoster virus virus-like particles
JP5711972B2 (ja) * 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えrsv抗原
WO2009108689A1 (en) * 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
KR101027159B1 (ko) * 2008-07-28 2011-04-05 뮤추얼아이피서비스(주) 타겟 영상 검출 장치 및 그 방법
WO2010077712A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
PL2370099T3 (pl) * 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania

Also Published As

Publication number Publication date
WO2013049342A1 (en) 2013-04-04
RU2014117068A (ru) 2015-11-10
EP2760469A4 (en) 2015-03-18
US20170319682A1 (en) 2017-11-09
US20130122032A1 (en) 2013-05-16
CN104080476A (zh) 2014-10-01
AU2013201495A1 (en) 2013-04-18
HK1222125A1 (zh) 2017-06-23
AU2013201495B2 (en) 2015-12-03
IL231637A0 (en) 2014-05-28
EP2760469A1 (en) 2014-08-06
US20150335730A1 (en) 2015-11-26
SG11201400999VA (en) 2014-07-30
KR20140077169A (ko) 2014-06-23
MX2014003777A (es) 2015-05-15
SG10201602434UA (en) 2016-05-30
CN105381457A (zh) 2016-03-09
CA2849471A1 (en) 2013-04-04
JP2014530010A (ja) 2014-11-17
US20150306207A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
BR112014007616A2 (pt) vacina de nanopartícula f de rsv recombinante para o vírus sincicial respiratório
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
NZ630649A (en) Vaccine against rsv
EA201270063A1 (ru) Рекомбинантные антигены pcb
PH12018500916A1 (en) Antibody neutralizing human respiratory syncytial virus
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
MX2012000036A (es) Vacuna.
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
MX387277B (es) Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
EA201290956A1 (ru) Вакцина против вич
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
EA201690115A1 (ru) Комбинированные иммуногенные композиции
MX363149B (es) Vacunas de nucleoproteina de la influenza.
EA201590124A1 (ru) Композиции и способы лечения или предупреждения пневмовирусной инфекции и связанных заболеваний
DK201370530A (en) Salmonid alphavirus vaccine
EA201592298A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
MX2014014521A (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
AR087811A1 (es) Vacuna contra el staphylococcus aureus
EA201592299A1 (ru) Полуживая вирусная вакцина против респираторно-синцитиального вируса
PL406631A1 (pl) Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie
PH12014502086B1 (en) Vaccine against rsv

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI